Over the past 5 years, the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) has continued its upward trajectory in cancer research excellence and service to its catchment area. The WFBCCC catchment area includes the Piedmont and southern Appalachia, a region of 58 contiguous counties in North Carolina, Virginia, West Virginia and Tennessee. The majority of this region is rural and exhibits significant racial health disparities. Elevated age-adjusted smoking rates, obesity rates, cancer incidence, and cancer mortality are observed across the WFBCCC catchment area when compared with the rest of the U.S. To target these issues, the WFBCCC conducts cutting-edge basic, clinical, and population research on the prevention, detection and treatment of cancer, and translates this knowledge into strategies to improve patient outcomes and reduce the incidence of cancer. WFBCCC cancer research funding is $37.9 million, of which over $14.9 million comes from the NCI; this represents a 25.3% increase in total cancer funding since the last CCSG renewal. Center research space under the Director?s authority increased by approximately 65,000 square feet, and the WFBCCC clinical facilities have been dramatically enhanced with the completion of the new eleven- story Cancer Hospital in 2013. This building houses all oncology inpatients and outpatients. The Center?s 127 members span the basic, clinical and population sciences and are organized into 4 Programs with substantial inter-and intra-programmatic productivity. Faculty additions enhanced tobacco control, tobacco-related cancer research, and precision medicine. Substantial investment in faculty, technology, and informatics significantly expanded cancer genomics capabilities. Enrollment of patients into treatment trials reached an all-time high in 2015, with a large increase in the number of patients enrolled in investigator-initiated trials. WFBCCC population scientists initiated exciting new efforts in cancer prevention and survivorship. Clinical scientists completed practice-changing studies in patients with glioma and lung cancer. Groundbreaking observations in prostate cancer emerged from WFBCCC inter-programmatic collaborations. WFBCCC basic science Programs continued to make high impact observations that are being translated into human therapeutics. The WFBCCC requests continued CCSG funding for 4 scientific Programs; 7 Shared Resources; 2 clinical research components; administration and leadership; planning and evaluation; and developmental funds. With these funds, a talented faculty integrated throughout the Cancer Center will make advances in the prevention, early detection, and treatment of cancer in the WFBCCC catchment area and the nation.
The Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) is a matrix Cancer Center, which serves the people of the multistate Piedmont and southern Appalachian region. The WFBCCC is the hub for clinical, basic, and population researchers focused on the prevention and early detection of cancer, developing novel cancer therapy, and improving the health of cancer survivors. WFBCCC is integral to the research mission of the Wake Forest Baptist Medical Center (WFBMC) in Winston-Salem, North Carolina, and is one of its largest research components. The WFBCCC unites the cancer research capabilities of multiple institutional units including the WFBMC, Wake Forest University and the Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences. The WFBCCC serves a broad educational mission for Wake Forest University students and faculty as well as for practitioners and caregivers across the region. The WFBCCC strives to reduce cancer incidence, morbidity and mortality regionally, nationally, and internationally through cutting-edge research and treatments, education and outreach, and multi- disciplinary training.
|Chouliaras, Konstantinos; Levine, Edward A; Fino, Nora et al. (2017) Prognostic Factors and Significance of Gastrointestinal Leak After Cytoreductive Surgery (CRS) with Heated Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol 24:890-897|
|Keim-Malpass, Jessica; Mihalko, Shannon L; Russell, Greg et al. (2017) Problems Experienced by Ovarian Cancer Survivors During Treatment. J Obstet Gynecol Neonatal Nurs 46:544-554|
|Wang, Lulu; Habib, Amyn A; Mintz, Akiva et al. (2017) Phosphatidylserine-Targeted Nanotheranostics for Brain Tumor Imaging and Therapeutic Potential. Mol Imaging 16:1536012117708722|
|Rohlfing, Matthew L; Mays, Ashley C; Isom, Scott et al. (2017) Insurance status as a predictor of mortality in patients undergoing head and neck cancer surgery. Laryngoscope 127:2784-2789|
|Ivey, Jill W; Latouche, Eduardo L; Richards, Megan L et al. (2017) Enhancing Irreversible Electroporation by Manipulating Cellular Biophysics with a Molecular Adjuvant. Biophys J 113:472-480|
|Park, Sun H; Eber, Matthew R; Tsuzuki, Shunsuke et al. (2017) Adeno-associated virus serotype rh10 is a useful gene transfer vector for sensory nerves that innervate bone in immunodeficient mice. Sci Rep 7:17428|
|Soto-Pantoja, David R; Wilson, Adam S; Clear, Kenysha Yj et al. (2017) Unfolded protein response signaling impacts macrophage polarity to modulate breast cancer cell clearance and melanoma immune checkpoint therapy responsiveness. Oncotarget 8:80545-80559|
|Carpenter, Richard L; Sirkisoon, Sherona; Zhu, Dongqin et al. (2017) Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Oncotarget 8:73947-73963|
|Andrews, Rachel N; Metheny-Barlow, Linda J; Peiffer, Ann M et al. (2017) Cerebrovascular Remodeling and Neuroinflammation is a Late Effect of Radiation-Induced Brain Injury in Non-Human Primates. Radiat Res 187:599-611|
|Wajih, Nadeem; Basu, Swati; Jailwala, Anuj et al. (2017) Potential therapeutic action of nitrite in sickle cell disease. Redox Biol 12:1026-1039|
Showing the most recent 10 out of 481 publications